RT Journal
A1 Ahluwalia JS, Harris K, Catley D, Okuyemi KS, Mayo MS
T1 Sustained-release bupropion for smoking cessation in african americans: A randomized controlled trial
JF JAMA
JO JAMA
YR 2002
FD July 24
VO 288
IS 4
SP 468
OP 474
DO 10.1001/jama.288.4.468
UL http://dx.doi.org/10.1001/jama.288.4.468
AB Context 
                  African Americans disproportionately experience greater smoking attributable
morbidity and mortality. Few clinical trials for smoking cessation in African
Americans have been conducted, despite a different profile of both smoking
and quitting patterns.Objective 
                  To compare a sustained-release form of bupropion hydrochloride (bupropion
SR) with placebo for smoking cessation among African Americans.Design, Setting, and Participants 
                  Randomized, double-blind, placebo-controlled trial conducted from February
11, 1999, to December 8, 2000, of 600 African American adults treated at a
community-based health care center. Volunteers, who smoked 10 or more cigarettes
per day were recruited by targeted media and health care professionals.Intervention 
                  Participants were randomly assigned to receive 150 mg of bupropion SR
(n = 300) or placebo (n = 300) twice daily for 7 weeks. Brief motivational
counseling was provided in-person at baseline, quit day, weeks 1 and 3, end
of treatment (week 6), and by telephone at day 3 and weeks 5 and 7.Main Outcome Measures 
                  Biochemically confirmed 7-day point prevalence abstinence at weeks 6
and 26 following quit day.Results 
                  Using intention-to-treat procedures, confirmed abstinence rates at the
end of 7 weeks of treatment were 36.0% in the bupropion SR group and 19.0%
in the placebo group (17.0 percentage point difference; 95% confidence interval,
9.7-24.4; P<.001). At 26 weeks the quit rates
were 21.0% in the treatment and 13.7% in the placebo groups (7.3 percentage
point difference; 95% confidence interval, 1.0-13.7; P
= .02). Those taking bupropion SR experienced a greater mean reduction in
depression symptoms at week 6 (2.96 [9.45] vs 1.13 [8.84]) than those taking
placebo, and after controlling for continuous abstinence, those taking bupropion
SR also gained less weight than those taking placebo.Conclusions 
                  Bupropion SR was effective for smoking cessation among African Americans
and may be useful in reducing the health disparities associated with smoking.